Variables NVP group n=71 LPV/r group n=94 p
Age(years)* 42 (38-45) 41 (37-44) 0.2
Male gender no. (%) 47 (66) 76 (81) 0.03
Body mass index (Kg/m2)* 22.8 (20.5-24.4) 23.2 (21.7-24.9) 0.5
HCV infection      
Former IDU no. (%) 55 (76) 81 (86) 0.1
Baseline HCV-RNA <600000 IU/mL no. (%) 40 (56) 25 (27) 0.001
Cirrhosis no.(%)† 3 (6) 22 (32) 0.001
Baseline serum ALT(IU/L)* 71 (45-100) 69 (45-100) 0.8
HCV genotype no. (%)   0.8
1 32 (45) 47 (50)  
2 1 (1) 2 (2)
3 26 (37) 32 (34)
4 12 (17) 13 (14)
HCV therapy      
Use of peg-IFN alfa-2a no.(%) 52 (73) 78 (83) 0.1
RBV dose/weight (mg/Kg/day)* 15.3 (13.8-16.4) 14.5 (13.4-16.1) 0.1
Starting HCV therapy from 2000 to 2004 no. (%) 25 (35) 26 (28) 0.3
Peg-IFN plus RBV during 24 weeks no. (%) 11 (15) 10 (11) 0.3
Time from starting NVP or LPV/r to beginning HCV therapy (months)* 39 (26-66) 20 (10-29) 0.001
Compliance with HCV therapy≥80% no. (%) 65 (91) 83 (88) 0.5
Use of growth factors no. (%) 3 (4) 10 (11) 0.1
HIV infection      
CDC C Clinical category no. (%) 14 (20) 32 (34) 0.04
Time with undetectable HIV viral load before starting HCV therapy (months)* 62 (29-84) 24 (14-58) 0.002
Baseline CD4 cell counts/mm3* 489 (338-658) 445 (300-589) 0.3
Baseline undetectable HIV viral load, no. (%) 68 (95) 77 (82) 0.007
Baseline LDL-cholesterol (mg/dL)* 100 (85-122) 84 (70-109) 0.07
Use of FTC no. (%) 26 (37) 35 (37) 0.9
*Median (Q1-Q3); † Liver biopsy was available in 47 individuals in the nevirapine (NVP) group and in 69 subjects in the lopinavir/ritonavir (LPV/r) group. IDU: intravenous drug user. ALT: alanine aminotransferase. peg-IFN: pegylated interferon. RBV: ribavirin. LDL: low-density lipoprotein. FTC: emtricitabine.
Table 1: Main features of both treatment groups.
Goto home»